Cargando…

ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide, with late detection, ineffective treatment and poor overall survival. Immunotherapy, including immune checkpoint inhibitor (ICI) therapy, holds great potential for treatment of HCC. Although some patients respond well to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xinyao, Li, Dan, Zhu, Hua, Yu, Tao, Xiong, Xiaoxing, Xu, Ximing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428557/ https://www.ncbi.nlm.nih.gov/pubmed/37587505 http://dx.doi.org/10.1186/s12920-023-01624-6

Ejemplares similares

The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors
por: Zhu, Hua, et al.
Publicado: (2022)

Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma
por: Hu, Xinyao, et al.
Publicado: (2022)

Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma
por: Hu, Xinyao, et al.
Publicado: (2023)

APOL4, a Novel Immune-Related Prognostic Biomarker for Glioma
por: Zhu, Hua, et al.
Publicado: (2022)

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy
por: Myojin, Yuta, et al.
Publicado: (2022)

Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role
por: Zhu, Hua, et al.
Publicado: (2021)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker
por: Hu, Xinyao, et al.
Publicado: (2021)

N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma
por: Cai, Jihao, et al.
Publicado: (2021)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma
por: Zhang, Shirong, et al.
Publicado: (2022)

Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Zhang, Genhao, et al.
Publicado: (2022)

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
por: Tai, David, et al.
Publicado: (2019)

Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
por: Ao, Huang, et al.
Publicado: (2021)

Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy
por: Xu, Qianhui, et al.
Publicado: (2021)

Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma
por: Xiong, Xiaofeng, et al.
Publicado: (2023)

HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
por: Chen, Guoming, et al.
Publicado: (2023)

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
por: Gok Yavuz, Betul, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

HMGB1 Promotes Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cells by Inducing Autophagy via the AMPK/mTOR Signaling Pathway
por: Li, Junhua, et al.
Publicado: (2021)

Intelectin-1 is a novel prognostic biomarker for hepatocellular carcinoma
por: Li, Jiang, et al.
Publicado: (2023)

Prognostic stratification based on m(5)C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Ping, et al.
Publicado: (2022)

Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma
por: Yang, Cheng, et al.
Publicado: (2022)

Comprehensive Analysis of ATP6V1s Family Members in Renal Clear Cell Carcinoma With Prognostic Values
por: Li, Xiaojuan, et al.
Publicado: (2020)

An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment
por: Du, Yingxi, et al.
Publicado: (2021)

Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma
por: Zhang, Qifan, et al.
Publicado: (2021)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Immunotherapies for hepatocellular carcinoma
por: Liu, Justin K. H., et al.
Publicado: (2021)

H2AFX might be a prognostic biomarker for hepatocellular carcinoma
por: Hu, Hailiang, et al.
Publicado: (2022)

Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma
por: Huang, Yugang, et al.
Publicado: (2021)

Prognostic Biomarker DDOST and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma
por: Zhu, Changyu, et al.
Publicado: (2022)

A novel seven-gene signature as Prognostic Biomarker in Hepatocellular Carcinoma
por: Xie, Hui, et al.
Publicado: (2020)

Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma
por: Yang, Yuping, et al.
Publicado: (2022)

IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma
por: Liu, Chengdong, et al.
Publicado: (2022)

Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers
por: Kwee, Sandi A., et al.
Publicado: (2021)

Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review)
por: Cheng, Mo, et al.
Publicado: (2023)

Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma
por: Tian, Bao-Wen, et al.
Publicado: (2022)

Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma
por: Han, Xiao-Yong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cajk4mtv5j3817bflqrva6osuv